Cancer Research AACR Conference on Molecular Diagnostics - 2008 Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Combaret, V.
Right arrow Articles by Puisieux, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Combaret, V.
Right arrow Articles by Puisieux, A.
[Cancer Research 62, 3646-3648, July 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Circulating MYCN DNA as a Tumor-specific Marker in Neuroblastoma Patients1

Valérie Combaret, Carole Audoynaud, Isabelle Iacono, Marie-Christine Favrot, Matthias Schell, Christophe Bergeron and Alain Puisieux2

Centre Léon Bérard, 69008 Lyon, France [V. C., C. A., I. I., M. S., C. B., A. P.], and CHUR Michallon, Hôpital de la Tronche, Cancérologie Biologique et Biothérapies, 38009 Grenoble, France [M. C. F.]

MYCN oncogene amplification is an established indicator of the aggressiveness of neuroblastomas; it is used internationally for stratifying patients for therapy. The present study shows that high levels of MYCN DNA sequences are present in the peripheral blood of patients with MYCN-amplified neuroblastomas. Circulating MYCN DNA may be a powerful and noninvasive prognostic marker at the time of diagnosis. Furthermore, preliminary data strongly suggest that the release of MYCN sequences in the peripheral blood is an early process in disease progression, permitting us to propose this novel marker for the follow-up of patients after chemotherapy.




This article has been cited by other articles:


Home page
 JCOHome page
V. Combaret, C. Bergeron, R. Noguera, I. Iacono, and A. Puisieux
Circulating MYCN DNA Predicts MYCN-Amplification in Neuroblastoma
J. Clin. Oncol., December 1, 2005; 23(34): 8919 - 8920.
[Full Text] [PDF]

Home page
 JCOHome page
T. Gotoh, H. Hosoi, T. Iehara, K. Tsuchiya, T. Sugimoto, and A. Nakagawara
In Reply:
J. Clin. Oncol., December 1, 2005; 23(34): 8920 - 8920.
[Full Text] [PDF]

Home page
 JCOHome page
T. Gotoh, H. Hosoi, T. Iehara, Y. Kuwahara, S. Osone, K. Tsuchiya, M. Ohira, A. Nakagawara, H. Kuroda, and T. Sugimoto
Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction
J. Clin. Oncol., August 1, 2005; 23(22): 5205 - 5210.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.